|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marquardt JU and Thorgeirsson SS:
SnapShot: Hepatocellular carcinoma. Cancer Cell. 25:550.e5512014.
View Article : Google Scholar
|
|
3
|
Agrawal S, Agarwal S, Arnason T, Saini S
and Belghiti J: Management of hepatocellular adenoma: Recent
advances. Clin Gastroenterol Hepatol. 13:1221–1230. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mehlen P and Puisieux A: Metastasis: A
question of life or death. Nat Rev Cancer. 6:449–458. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oishi N, Yamashita T and Kaneko S:
Molecular biology of liver cancer stem cells. Liver Cancer.
3:71–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bandiera S, Pfeffer S, Baumert TF and
Zeisel MB: miR-122 - a key factor and therapeutic target in liver
disease. J Hepatol. 62:448–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kota J, Chivukula RR, ODonnell KA, Wentzel
EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M,
Clark KR, et al: Therapeutic microRNA delivery suppresses
tumorigenesis in a murine liver cancer model. Cell. 137:1005–1017.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee CH, Kim JH and Lee SW: The role of
microRNAs in hepatitis C virus replication and related liver
diseases. J Microbiol. 52:445–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan Q, Loya K, Rani B, Möbus S,
Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, et
al: MicroRNA-221 overexpression accelerates hepatocyte
proliferation during liver regeneration. Hepatology. 57:299–310.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang JY, Zhang K, Chen DQ, Chen J, Feng
B, Song H, Chen Y, Zhu Z, Lu L, De W, et al: MicroRNA-451:
Epithelial-mesenchymal transition inhibitor and prognostic
biomarker of hepatocelluar carcinoma. Oncotarget. 6:18613–18630.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng Z, Liu J, Yang Z, Wu L, Xie H, Jiang
C, Lin B, Chen T, Xing C, Liu Z, et al: MicroRNA-452 promotes
stem-like cells of hepatocellular carcinoma by inhibiting Sox7
involving Wnt/β-catenin signaling pathway. Oncotarget.
7:28000–28012. 2016.PubMed/NCBI
|
|
13
|
Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong
S, Chen W, Yang J and Li H: MiR-1180 promotes apoptotic resistance
to human hepatocellular carcinoma via activation of NF-κB signaling
pathway. Sci Rep. 6:223282016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hall DP, Cost NG, Hegde S, Kellner E,
Mikhaylova O, Stratton Y, Ehmer B, Abplanalp WA, Pandey R, Biesiada
J, et al: TRPM3 and miR-204 establish a regulatory circuit that
controls oncogenic autophagy in clear cell renal cell carcinoma.
Cancer Cell. 26:738–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang M, Dong BB, Lu M, Zheng MJ, Chen H,
Ding JZ, Xu AM and Xu YH: miR-429 functions as a tumor suppressor
by targeting FSCN1 in gastric cancer cells. Onco Targets Ther.
9:1123–1133. 2016.PubMed/NCBI
|
|
17
|
Wu CL, Ho JY, Chou SC and Yu DS: MiR-429
reverses epithelial-mesenchymal transition by restoring E-cadherin
expression in bladder cancer. Oncotarget. 7:26593–26603.
2016.PubMed/NCBI
|
|
18
|
Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing
C, Gao K, Liu ZH and Yu SJ: miR-429 inhibits migration and invasion
of breast cancer cells in vitro. Int J Oncol. 46:531–538.
2015.PubMed/NCBI
|
|
19
|
Chen W, Zhang B, Guo W, Gao L, Shi L, Li
H, Lu S, Liu Y and Li X: miR-429 inhibits glioma invasion through
BMK1 suppression. J Neurooncol. 125:43–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu
Z, Li X and Wu M: MiR-429 inhibits cells growth and invasion and
regulates EMT-related marker genes by targeting Onecut2 in
colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lei W, Liu YE, Zheng Y and Qu L: MiR-429
inhibits oral squamous cell carcinoma growth by targeting ZEB1. Med
Sci Monit. 21:383–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and
Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell
lung cancer cells and targets multiple tumor suppressor genes.
Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang J, Li L, Huang W, Sui C, Yang Y, Lin
X, Hou G, Chen X, Fu J, Yuan S, et al: MiR-429 increases the
metastatic capability of HCC via regulating classic Wnt pathway
rather than epithelial-mesenchymal transition. Cancer Lett.
364:33–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Tang J, Zhang B, Yang W, LiuGao M,
Wang R, Tan Y, Fan J, Chang Y, Fu J, et al: Epigenetic modification
of MiR-429 promotes liver tumour-initiating cell properties by
targeting Rb binding protein 4. Gut. 64:156–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao H and Liu C: miR-429 represses cell
proliferation and induces apoptosis in HBV-related HCC. Biomed
Pharmacother. 68:943–949. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bradley JR and Pober JS: Tumor necrosis
factor receptor-associated factors (TRAFs). Oncogene. 20:6482–6491.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chung JY, Park YC, Ye H and Wu H: All
TRAFs are not created equal: Common and distinct molecular
mechanisms of TRAF-mediated signal transduction. J Cell Sci.
115:679–688. 2002.PubMed/NCBI
|
|
28
|
Peng Z, Shuangzhu Y, Yongjie J, Xinjun Z
and Ying L: TNF receptor-associated factor 6 regulates
proliferation, apoptosis, and invasion of glioma cells. Mol Cell
Biochem. 377:87–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He Z, Huang C, Lin G and Ye Y:
siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits
the invasion of human lung cancer SPC-A1 cells. Oncol Rep.
35:1933–1940. 2016.PubMed/NCBI
|
|
30
|
Lin D, Zhang M, Zhang MX, Ren Y, Jin J,
Zhao Q, Pan Z, Wu M, Shu HB, Dong C, et al: Induction of USP25 by
viral infection promotes innate antiviral responses by mediating
the stabilization of TRAF3 and TRAF6. Proc Natl Acad Sci USA.
112:11324–11329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao F, Wang H, Fu X, Li Y and Wu Z: TRAF6
promotes myogenic differentiation via the TAK1/p38
mitogen-activated protein kinase and Akt pathways. PLoS One.
7:e340812012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Walsh MC, Lee J and Choi Y: Tumor necrosis
factor receptor- associated factor 6 (TRAF6) regulation of
development, function, and homeostasis of the immune system.
Immunol Rev. 266:72–92. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132.
2012.PubMed/NCBI
|
|
34
|
Starczynowski DT, Lockwood WW, Deléhouzée
S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL,
et al: TRAF6 is an amplified oncogene bridging the RAS and NF-κB
pathways in human lung cancer. J Clin Invest. 121:4095–4105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
